What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide this
Behavioural support and pharmacotherapy improve smoking quit rates in adults
Patnode CD, Henderson JT, Thompson JH, et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: A review of reviews for the U.S. preventive services task force Annals of Internal Medicine. 2015;163:608-621.
What are the benefits and harms of behavioural support and pharmacotherapy for tobacco cessation in adults, including pregnant women?
Are electronic nicotine delivery systems (ENDS) an effective and safe way to quit smoking?
Tobacco use and exposure to cigarette smoke is the leading cause of disease, disability and death, and annually causes over 480 000 early deaths in the United States. The U.S. Preventative Services Task Force recommended first in 2003 and again in 2009 that doctors talk to adults about the use of tobacco and provide assistance for quitting for those who smoke.
How the review was done
A review of reviews was conducted including reviews published between 2009 and 2014 that assessed the effectiveness of behavioral approaches and pharmacotherapy on smoking cessation among adults as well as pregnant women. In addition, a search for primary studies was conducted to assess the effectiveness and safety of ENDS on smoking cessation. There were 54 reviews included in this report and 2 primary studies.
- Behavioural approaches included: physician advice, tailored/non-tailored self-help material, phone counseling, in-person individual or group counselling, compared to no advice, usual care, medication, brief advice.
- Pharmacotherapy included: nicotine replacement therapy (NRT), bupropion or varenicline. Results were compared to placebo, one type of NRT, no NRT, no bupropion.
- ENDS included electronic cigarettes compared to NRT patches, placebo electronic cigarettes with voluntary quit line behavioural support, or electronic cigarettes with no nicotine.
- Smoking quit rates, health outcomes and adverse events were measured.
What the researchers found
General adult population:
- Health outcomes – significantly fewer men died from respiratory illnesses in the group who received quitting support vs. control group at 33 year follow-up.
- Quitting outcomes – counseling by physicians and nurses, tailored self-help print materials and phone counseling increased quitting at 6 months vs. minimal intervention/usual care. Minimal and intensive advice greatly increased quit rates vs. no advice, with intensive advice being more beneficial.
- Health outcomes: none of the reviews reported on health outcomes
- Quitting outcomes: NRT, bupropion, and varenicline improved quitting at 6 months or longer.
- Adverse events: no serious side effects associated with NRT and bupropion, but NRT linked to increased risk of minor cardiovascular events. Varenicline associated with increased risk of serious cardiovascular events.
Combined behavioral support and pharmaceuticals
- Combined use of behavioural support and NRT or bupropion significantly increased quitting at 6 months or longer vs. controls.
- ENDS offered no benefit on smoking cessation among those planning to quit.
- No significant difference in adverse side effects between ENDS group and NRT patch group.
- Behavioral support significantly improved quit rates, while NRT showed no significant benefit.
Behavioural support and pharmacotherapy improve smoking quit rates in adults, both when alone or combined. Behavioural support is most effective among pregnant women, and electronic delivery systems are not effective for smoking cessation among those intending to quit.
A group that receives either no treatment or a standard treatment.
A harmless, inactive, and simulated treatment.
The body's network of blood vessels. It includes the arteries, veins, and capillaries that carry blood to and from the heart.
Related Evidence Summaries
Cochrane Database of Systematic Reviews (2016)
British Journal of Clinical Pharmacology (2016)
JAMA Internal Medicine (2016)
Related Web Resources
This patient decision aid helps adults with rheumatoid arthritis decide on whether or not to take tocilizumab (Actemra®) by comparing the benefits and side effects of both options.
This patient decision aid helps adults with rheumatoid arthritis decide on whether to take methotrexate (Rheumatrex®) alone or with other disease modifying anti-rheumatic drugs by comparing the benefits and side effects of both options.
This patient decision aid helps adults with rheumatoid arthritis decide on whether or not to take abatacept (Orencia®) by comparing the benefits and side effects of both options.
DISCLAIMER These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal